Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Invesco Ltd. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $288.04 (market cap $39.89B), while Invesco Ltd. trades at $28.48 (market cap $12.85B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 3.1× Invesco Ltd.'s market cap, and Invesco Ltd. pays a 2.97% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | IVZ | |
|---|---|---|
Market Cap | $39.89B | $12.85B |
Sector | Health | Financials |
52-Week High | $491.22 | $29.44 |
52-Week Low | $278.09 | $16.74 |
Enterprise Value | $38.15B | $23.09B |
Dividend Yield | — | 2.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
IVZ trades at $28.98, up 1.29% today, with a bullish technical signal and analyst consensus price target of $29.79. Recent earnings show mixed results, beating in Q3 and Q4 2025 but missing in Q1 2026, while the company reported a net loss of $281.70 million in 2025. Positive cash flow from operations of $1.53 billion and a recent dividend payment of $0.22 per share highlight financial stability amid profitability challenges.
The outlook for IVZ is cautiously optimistic, supported by strong analyst buy ratings and improving assets under management, but weighed down by negative net income margins and competitive pressures in asset management. Key risks include execution on profitability and market volatility affecting AUM growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
